KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash from Operations: 2012-2024

Historic Cash from Operations for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to -$181.4 million.

  • Xenon Pharmaceuticals' Cash from Operations fell 44.47% to -$71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$252.0 million, marking a year-over-year decrease of 55.18%. This contributed to the annual value of -$181.4 million for FY2024, which is 20.04% down from last year.
  • Xenon Pharmaceuticals' Cash from Operations amounted to -$181.4 million in FY2024, which was down 20.04% from -$151.1 million recorded in FY2023.
  • In the past 5 years, Xenon Pharmaceuticals' Cash from Operations registered a high of -$48.1 million during FY2020, and its lowest value of -$181.4 million during FY2024.
  • In the last 3 years, Xenon Pharmaceuticals' Cash from Operations had a median value of -$151.1 million in 2023 and averaged -$144.5 million.
  • Data for Xenon Pharmaceuticals' Cash from Operations shows a maximum YoY slumped of 920.87% (in 2020) over the last 5 years.
  • Xenon Pharmaceuticals' Cash from Operations (Yearly) stood at -$48.1 million in 2020, then slumped by 44.42% to -$69.5 million in 2021, then crashed by 45.36% to -$101.0 million in 2022, then tumbled by 49.57% to -$151.1 million in 2023, then dropped by 20.04% to -$181.4 million in 2024.